Developments Hemogenyx, Cellin sign LOI to commercialize cell therapy for R/R AML in Estonia Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the signing of a letter of intent (LOI) with closely held Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for the treatment of... September 23, 2025